ERBB2 and neoplasm: In comparison to trastuzumab or pertuzumab, ZW25 exhibits stronger anti-tumor activity, effectively suppresses HER2 signaling, and enhances immune system activation and antibody-dependent cellular cytotoxicity (ADCC) effects (46, 47).